| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 10.02.
| Pharmacyclics Shares Surged: What You Need to Know | | 2 | Motley Fool |
| 09.02.
| Pharmacyclics rises after posting 2Q profit | | 1 | Yahoo-USA |
| 09.02.
| PHARMACYCLICS INC - 10-Q, Quarterly Report | | 1 | SEC Filings |
| 09.02.
| Pharmacyclics Crosses Above its 10-day MA | | 1 | SmarTrend |
| 09.02.
| Pharmacyclics Reports Fiscal 2012 Second Quarter Financial Results | | 59 | PR Newswire |
| SUNNYVALE, Calif., Feb. 9, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results and recent developments for its fiscal second quarter ended December 31, 2011.
Financial...
Mehr lesen zu:
Pharmacyclics Reports Fiscal 2012 Second Quarter Financial Results | |
| 27.01.
| Pharmacyclics: The Winning Streak Continues | | 3 | SmarTrend |
| 25.01.
| Uptrend Call Working As Pharmacyclics Stock Rises 15.6% | | 1 | SmarTrend |
| 24.01.
| Pharmacyclics: 52-Week High Recently Eclipsed | | 1 | SmarTrend |
| 13.01.
| Stock Investors Sell Off Shares of Pharmacyclics, Down 5.1% | | 2 | SmarTrend |
| 11.01.
| Watch for Continued Gains in Shares of Pharmacyclics | | 4 | SmarTrend |
| 19.12.
| Pharmacyclics Inc. Receives Issue Notice of Significant Bruton's Tyrosine Kinase (BTK) Patent | | 21 | PR Newswire |
| SUNNYVALE, Calif., Dec. 19, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs...
Mehr lesen zu:
Pharmacyclics Inc. Receives Issue Notice of Significant Bruton's Tyrosine Kinase (BTK) Patent | |
| 14.12.
| Shares of Pharmacyclics Are Up on Strong Volume | | 1 | SmarTrend |
| 13.12.
| Pharmacyclics (PCYC) Updates on BTK Inhibitor PCI-32765 Phase Ib/II in CLL/SLL Patients | | 1 | StreetInsider.com |
| 13.12.
| Pharmacyclics® Announces Updated Results for BTK Inhibitor PCI-32765 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma at American Society for Hematology (ASH) Annual Meeting | | 61 | PR Newswire |
| SAN DIEGO, Dec. 13, 2011 /PRNewswire/ --Pharmacyclics, Inc (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs...
Mehr lesen zu:
Pharmacyclics® Announces Updated Results for BTK Inhibitor PCI-32765 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma at American Society for Hematology (ASH) Annual Meeting | |
| 12.12.
| Pharmacyclics® Reports Interim Phase II Trial Results for BTK Inhibitor PCI-32765 in Mantle Cell Lymphoma at American Society of Hematology (ASH) Annual Meeting | | 80 | PR Newswire |
| SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment...
Mehr lesen zu:
Pharmacyclics® Reports Interim Phase II Trial Results for BTK Inhibitor PCI-32765 in Mantle Cell Lymphoma at American Society of Hematology (ASH) Annual Meeting | |
| 11.12.
| Pharmacyclics' blood cancer drug responses rise | | 3 | Reuters.com |
| 08.12.
| Pharmacyclics Forms Deal With Janssen Biotech To Develop,Commercialize PCI-32765 | | 114 | AFX News |
| NEW BRUNSWICK (dpa-AFX) - Pharmacyclics Inc. (PCYC), announced that it has
entered into a worldwide collaboration with Janssen Biotech Inc., one of the
Janssen Pharmaceutical Companies of...
Mehr lesen zu:
Pharmacyclics Forms Deal With Janssen Biotech To Develop,Commercialize PCI-32765 | |
| 08.12.
| Janssen Biotech (JNJ) Announces Agreement with Pharmacyclics (PCYC) to Devlop Anti-Cancer Compound | | 1 | StreetInsider.com |
| 08.12.
| Pharmacyclics (PCYC) Enters PCI-32765 Collaboration w/ J&J (JNJ) Unit; to Get $150M Upfront | | - | StreetInsider.com |
| 08.12.
| Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc. | | 44 | PR Newswire |
| SUNNYVALE, Calif., Dec. 8, 2011 /PRNewswire/ --Pharmacyclics, Inc. (Nasdaq: PCYC), announced today that it has entered into a worldwide collaboration with Janssen Biotech, Inc., one...
Mehr lesen zu:
Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc. | |
